Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients

The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine founded by Drs. John Mendelsohn and Thomas Tursz provided a vision for innovation, collaboration and global impact in precision oncology. Through pursuit of transcriptomic signatures, artificial intelligence (AI) algorithms, global precision cancer medicine clinical trials and input from an international Molecular Tumor Board (MTB), WIN has led the way in demonstrating patient benefit from precision-therapeutics through N-of-1 molecularly-driven studies. WIN Next-Generation Precision Oncology (WINGPO) trials are being developed in the neoadjuvant, adjuvant or metastatic settings, incorporate real-world data, digital pathology, and advanced algorithms to guide MTB prioritization of therapy combinations for a diverse global population. WIN has pursued combinations that target multiple drivers/hallmarks of cancer in individual patients. WIN continues to be impactful through collaboration with industry, government, sponsors, funders, academic and community centers, patient advocates, and other stakeholders to tackle challenges including drug access, costs, regulatory barriers, and patient support. WIN's collaborative next generation of precision oncology trials will guide treatment selection for patients with advanced cancers through MTB and AI algorithms based on serial liquid and tissue biopsies and exploratory omics including transcriptomics, proteomics, metabolomics and functional precision medicine. Our vision is to accelerate the future of precision oncology care.

Authors

Institutions

Publication Details

Journal
Oncotarget
Published
2025-03-12
DOI
https://doi.org/10.18632/oncotarget.28703
Citations
2
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
1.87
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients

Luis F. Oñate‐Ocaña, Steven K. Libutti, Jair Bar, Finn Cilius Nielsen et al.
2 citations
Oncotarget
Cancer Genomics and Diagnostics
1.87
article

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients

Luis F. Oñate‐Ocaña, Steven K. Libutti, Jair Bar, Finn Cilius Nielsen, Gregory Riedlinger, Roy S. Herbst, Ibrahim Abu-Gheida, Mohamed E. Salem, Alejandro Piris Gimenez, Humaid Obaid Al-Shamsi, Howard Safran, Alberto Hernando‐Calvo, Eitan Rubin, Josep M. Tabernero, Sadakatsu Ikeda, Roger R. Reddel, William L. Dahut, Abdulrouf Pallivalapila, Fanny Wunder, Christina M. Annunziata, Gerald Batist, Carol Farhangfar, Richard L. Schilsky, Hikmat Abdel‐Razeq, Ramón Salazar, Rui Manuel Reis, Alexandre Archanjo Ferraro, Jassim Al Suwaidi, Angel Porgador, Ruben A. Mesa, Manon Gantenbein, Don S. Dizon, Rareş Buiga, Himabindu Gaddipati, Casey Williams, Guy Berchem, Marina Sekacheva, Jeremy L. Warner, Apostolia Maria Tsimberidou, Eric T. Wong, Christopher G. Azzoli, Catherine Bresson, Shai Magidi, Khaled M. Musallam, Eugenia Girda, Stephanie L. Graff, Olivier Elemento, Raanan Berger, Jens Rueter, Ioana Berindan‐Neagoe, Pierre Saintigny, Benedito A. Carneiro, Amir Onn, Yves A. Lussier, Mandar Kulkarni, Wafik S. El‐Deiry, Sendurai A. Mani, Andrés Cervantes Valarezo, Cristiano de Pádua Souza, Anthony M. Joshua, Leah Graham, Benjamin Solomon, Adel T. Aref, Amal Al‐Omari, Sewanti Atul Limaye, Said Dermime, Enriqueta Felip, Maria Gerogianni, Jia Liu, Zhen Chen, Liang Cheng, Tobias Meißner, Bishoy M. Faltas, Razelle Kurzrock, Jacques Raynaud, Jim Palma, Naftali Z. Frankel, Cătălin Ioan Vlad, Manju Sengar, Satoru Aoyama, C.S. Pramesh, Mohammed Ussama Al Homsi, Kerri Gober, Elisabeth Auzias, Nicolas Wolikow, Simon Istolainen, Pessie Schlafrig
article en
2 citations

Abstract

The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine founded by Drs. John Mendelsohn and Thomas Tursz provided a vision for innovation, collaboration and global impact in precision oncology. Through pursuit of transcriptomic signatures, artificial intelligence (AI) algorithms, global precision cancer medicine clinical trials and input from an international Molecular Tumor Board (MTB), WIN has led the way in demonstrating patient benefit from precision-therapeutics through N-of-1 molecularly-driven studies. WIN Next-Generation Precision Oncology (WINGPO) trials are being developed in the neoadjuvant, adjuvant or metastatic settings, incorporate real-world data, digital pathology, and advanced algorithms to guide MTB prioritization of therapy combinations for a diverse global population. WIN has pursued combinations that target multiple drivers/hallmarks of cancer in individual patients. WIN continues to be impactful through collaboration with industry, government, sponsors, funders, academic and community centers, patient advocates, and other stakeholders to tackle challenges including drug access, costs, regulatory barriers, and patient support. WIN's collaborative next generation of precision oncology trials will guide treatment selection for patients with advanced cancers through MTB and AI algorithms based on serial liquid and tissue biopsies and exploratory omics including transcriptomics, proteomics, metabolomics and functional precision medicine. Our vision is to accelerate the future of precision oncology care.

OncotargetVol. 16(1)
Université Claude Bernard Lyon 1 (FR), Rutgers, The State University of New Jersey (US), Ben-Gurion University of the Negev (IL), American Cancer Society (US), Centre National de la Recherche Scientifique (FR), The University of Sydney (AU), The University of Texas MD Anderson Cancer Center (US), Children's Medical Research Institute (AU), Inserm (FR), Centre Hospitalier de Luxembourg (LU), Tel Aviv University (IL), Sechenov University (RU), University of Luxembourg (LU), Homi Bhabha National Institute (IN), Medical College of Wisconsin (US), Cornell University (US), Iuliu Hațieganu University of Medicine and Pharmacy (RO), University of Utah (US), Brown University (US), King Hussein Cancer Center (JO), Sir H.N. Reliance Foundation Hospital and Research Centre (IN), Avera Health (US), Sheba Medical Center (IL), Tata Memorial Hospital (IN), Jewish General Hospital (CA), Rigshospitalet (DK), UNSW Sydney (AU), Yale University (US), Academia Oamenilor de Știință din România (RO), University of Chicago (US), Institut d'Investigació Biomédica de Bellvitge (ES), St Vincent's Hospital Melbourne (AU), Hospital de Câncer de Barretos (BR), Fudan University Shanghai Cancer Center (CN), Institute of Oncology Prof. Dr. Ion Chiricuta (RO), Luxembourg Institute of Health (LU), Centre Léon Bérard (FR), Institut Català d'Oncologia (ES), Jackson Laboratory (US), National Center for Cancer Care and Research (QA), TargetCancer Foundation (US), Centre de Recherche en Cancérologie de Lyon (FR), Vall d'Hebron Hospital Universitari (ES), The Kinghorn Cancer Centre (AU), Instituto Nacional de Cancerología (MX), INCLIVA Health Research Institute (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), Wake Forest University (US), Hamad Medical Corporation (QA), McGill University (CA), Universitat de Barcelona (ES), University of Minho (PT)
Partnerships for the goals
Openalex Percentile: Top 16%
Cancer Genomics and Diagnostics
1.87
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.